Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo

Virology

Volumn 320, Issue 1, 2004, Pages 121-134

  Rivera, Angel A ^a   Wang, Minghui ^a   Suzuki, Kaori ^a   Uil, Taco G ^a,c   Krasnykh, Victor ^a,d   Curiel, David T ^a   Nettelbeck, Dirk M ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Armed oncolytic adenovirus; Conditionally replicative adenovirus; Early and late transgene expression; Gene therapy; IRES; Timing of transgene expression; Viral oncolysis; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE; ONCOLYTIC VIRUS; RECOMBINANT DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME ACTIVITY; ENZYME KINETICS; FEMALE; GENE CASSETTE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE FUSION; GENE INSERTION SEQUENCE; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; INJECTION SITE; INTERNAL RIBOSOME ENTRY SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SPECIES COMPARISON; TRANSGENE; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E2 PROTEINS; ANIMALS; ARTIFICIAL GENE FUSION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, VIRAL; GENETIC VECTORS; HUMANS; LUCIFERASES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS; RIBOSOMES; RNA, MESSENGER; TIME FACTORS; TRANSGENES;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS; INSERTION SEQUENCES;

EID: 1542270866     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.11.028     Document Type: Article

References (43)

1. Akbulut H., Zhang L., Tang Y., Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther. 10(5):2003;388-395.
2. Alemany R., Balague C., Curiel D.T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18(7):2000;723-727.
3. Attal J., Theron M.C., Puissant C., Houdebine L.M. Effect of intercistronic length on internal ribosome entry site (IRES) efficiency in bicistronic mRNA. Gene Expression. 8(5-6):1999;299-309.
4. Bernt K.M., Steinwaerder D.S., Ni S., Li Z.Y., Roffler S.R., Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 62(21):2002;6089-6098.
5. Bristol J.A., Zhu M., Ji H., Mina M., Xie Y., Clarke L., Forry-Schaudies S., Ennist D.L. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Molec. Ther. 7(6):2003;755-764.
6. Curiel D.T. The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res. 6(9):2000;3395-3399.
7. Doronin K., Toth K., Kuppuswamy M., Ward P., Tollefson A.E., Wold W.S. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74(13):2000;6147-6155.
8. Freytag S.O., Rogulski K.R., Paielli D.L., Gilbert J.D., Kim J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9(9):1998;1323-1333.
9. Fuerst T.R., Niles E.G., Studier F.W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 83(21):1986;8122-8126.
10. Fueyo J., Gomez M.C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., Shi Y.X., Levin V.A., Yung W.K., Kyritsis A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 19(1):2000;2-12.
11. Harries M., Phillipps N., Anderson R., Prentice G., Collins M. Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. J. Gene Med. 2(4):2000;243-249.
12. Hawkins L.K., Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 8(15):2001;1142-1148.
13. Hawkins L.K., Hermiston T.W. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther. 8(15):2001;1132-1141.
14. Hawkins L.K., Johnson L., Bauzon M., Nye J.A., Castro D., Kitzes G.A., Young M.D., Holt J.K., Trown P., Hermiston T.W. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 8(15):2001;1123-1131.
15. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95(5):1998;2509-2514.
16. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6(10):2000;1134-1139.
17. Hermiston T.W., Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 9(12):2002;1022-1035.
18. Kirn D.H., McCormick F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today. 2(12):1996;519-527.
19. Kobayashi T., Kida Y., Kaneko T., Pastan I., Kobayashi K. Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site. J. Gene Med. 3(5):2001;505-510.
20. Lambright E.S., Amin K., Wiewrodt R., Force S.D., Lanuti M., Propert K.J., Litzky L., Kaiser L.R., Albelda S.M. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. 8(12):2001;946-953.
21. Lee Y.J., Galoforo S.S., Battle P., Lee H., Corry P.M., Jessup J.M. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther. 8(6):2001;397-404.
22. Li Y., Yu D.C., Chen Y., Amin P., Zhang H., Nguyen N., Henderson D.R. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 61(17):2001;6428-6436.
23. Martinez-Salas E. Internal ribosome entry site biology and its use in expression vectors. Curr. Opin. Biotechnol. 10(5):1999;458-464.
24. Maxfield L.F., Spector D.J. Readthrough activation of early adenovirus E1b gene transcription. J. Virol. 71(11):1997;8321-8329.
25. Nanda D., Vogels R., Havenga M., Avezaat C.J., Bout A., Smitt P.S. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 61(24):2001;8743-8750.
26. Parks C.L., Banerjee S., Spector D.J. Organization of the transcriptional control region of the E1b gene of adenovirus type 5. J. Virol. 62(1):1988;54-67.
27. Peng K.W., Facteau S., Wegman T., O'Kane D., Russell S.J. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8(5):2002;527-531.
28. Rees, S., Coote, J., Stables, J., Goodson, S., Harris, S., and Lee, M.G. (1996). Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20 (1), 102-4, 106, 108-10.
29. Reid T., Warren R., Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9(12):2002;979-986.
30. Reynolds P.N., Nicklin S.A., Kaliberova L., Boatman B.G., Grizzle W.E., Balyasnikova I.V., Baker A.H., Danilov S.M., Curiel D.T. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. 19(9):2001;838-842.
31. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83(Pt. 3):2002;491-502.
32. Rogulski K.R., Wing M.S., Paielli D.L., Gilbert J.D., Kim J.H., Freytag S.O. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11(1):2000;67-76.
33. Sauthoff H., Pipiya T., Heitner S., Chen S., Norman R.G., Rom W.N., Hay J.G. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. 13(15):2002;1859-1871.
34. Seki T., Dmitriev I., Kashentseva E., Takayama K., Rots M., Suzuki K., Curiel D.T. Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines. J. Virol. 76(3):2002;1100-1108.
35. Suzuki K., Fueyo J., Krasnykh V., Reynolds P.N., Curiel D.T., Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7(1):2001;120-126.
36. Suzuki K., Alemany R., Yamamoto M., Curiel D.T. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8(11):2002;3348-3359.
37. van Beusechem V.W., van den Doel P.B., Grill J., Pinedo H.M., Gerritsen W.R. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62(21):2002;6165-6171.
38. Vassaux G., Groot-Wassink T. In vivo noninvasive imaging for gene therapy. J. Biomed. Biotechnol. 2003(2):2003;92-101.
39. Wildner O., Blaese R.M., Morris J.C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59(2):1999;410-413.
40. Wildner O., Morris J.C., Vahanian N.N., Ford H. Jr., Ramsey W.J., Blaese R.M. Adenoviral vectors capable of replication improve the efficacy of HSVtk/ GCV suicide gene therapy of cancer. Gene Ther. 6(1):1999;57-62.
41. Wu H., Seki T., Dmitriev I., Uil T., Kashentseva E., Han T., Curiel D.T. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum. Gene Ther. 13(13):2002;1647-1653.
42. Yu D.C., Sakamoto G.T., Henderson D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59(7):1999;1498-1504.
43. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6(2):1999;113-138.